Jaguar aims to leverage digital technologies including AI enhancement to help connect with investor communities
SAN FRANCISCO, CA / ACCESSWIRE / August 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (GI) prescription medicines, today announced it has engaged B2i Digital to execute an innovative digital investor engagement and awareness program. B2i will harness its investor platform and data-driven digital marketing expertise to highlight Jaguar's novel pipeline of prescription drugs sustainably derived from rainforest plants.